HR 6625 United States House · 117th Congress

Equal Access to Therapeutics Act

Summary
Equal Access to Therapeutics Act This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies). Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance. The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.
Bill status in committee 1 of 4 stages cleared
Introduction
Feb 2022
Committee Review
Floor Vote
President
Introduced Feb 7, 2022 Last action Feb 8, 2022
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
3
Key actions
0
Committee
2
Feb 8, 2022
Committee
Referred to the Subcommittee on Health.
lower
Feb 7, 2022
Committee
Referred to the House Committee on Energy and Commerce.
lower
Feb 7, 2022
Introduced
Introduced in House
lower
1 primary · 16 co-sponsors

Sponsors